Lidocaine Infusion As A Treatment Modality For Headache Following Non-Traumatic Subarachnoid Hemorrhage: A Prospective, Single-Center, Observational Cohort Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Subarachnoid; Hemorrhage, Nontraumatic
- Sponsor
- University of Kansas Medical Center
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Reduction of pain
- Status
- Recruiting
- Last Updated
- 9 months ago
Overview
Brief Summary
The goal of this observational study is to evaluate intravenous lidocaine efficacy and safety in treating headache following non-traumatic subarachnoid hemorrhage. Through this prospective analysis, the investigators hope to:
- show that intravenous lidocaine infusion causes a clinically significant reduction in pain scores in patients with moderate/severe headache pain following non-traumatic subarachnoid hemorrhage;
- show that intravenous lidocaine infusion is safe in treating headache following non-traumatic subarachnoid hemorrhage;
- and report vasospasm prevalence in the cohort.
Participants will receive lidocaine infusion as treatment for non-traumatic subarachnoid hemorrhage headache and provide pain scores (on a numeric pain scale) every two hours the patients are awake for a maximum of seven days. Monitoring for vasospasm will occur as part of the patients regular medical care.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients \> 18 years;
- •Have a favorable neurological status defined as Hunt and Hess score ≤ 3 (as it accounts for patient awareness);
- •Can communicate numeric pain scores;
- •Are diagnosed with non-traumatic subarachnoid hemorrhage
Exclusion Criteria
- •The patient is diagnosed with traumatic subarachnoid hemorrhage;
- •If the patient is \< 18 years of age;
- •If numeric pain scores could not be captured for \> 3 days of hospitalization;
- •If the patient had a prior aneurysm;
- •Chronic pain not associated with non-traumatic subarachnoid hemorrhage diagnosis;
- •A disability before the stroke (\> 2 on modified Rankin Scale score);
- •A Hunt and Hess score \> 3;
- •Contraindications to lidocaine (significant cardiac disease, arrhythmia, seizures, previous allergic reaction to lidocaine
Outcomes
Primary Outcomes
Reduction of pain
Time Frame: Benefit should be seen within first 24 h of infusion
Reduction of pain ≥ 2 points in the numeric pain score after lidocaine infusion treatment. The numeric pain score is a score rating severity of pain from 0 to 10, with higher scores meaning worse pain. The reduction in pain scores indicates a decrease in severity of pain.